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Abstract: G protein coupled receptors (GPCRs), also called 7TM receptors, form a huge superfamily of membrane proteins that, upon 
activation by extracellular agonists, pass the signal to the cell interior. Ligands can bind either to extracellular N-terminus and loops (e.g. 
glutamate receptors) or to the binding site within transmembrane helices (Rhodopsin-like family). They are all activated by agonists 
although a spontaneous auto-activation of an empty receptor can also be observed. Biochemical and crystallographic methods together 
with molecular dynamics simulations and other theoretical techniques provided models of the receptor activation based on the action of 
so-called “molecular switches” buried in the receptor structure. They are changed by agonists but also by inverse agonists evoking an 
ensemble of activation states leading toward different activation pathways. Switches discovered so far include the ionic lock switch, the 
3-7 lock switch, the tyrosine toggle switch linked with the nPxxy motif in TM7, and the transmission switch. The latter one was proposed 
instead of the tryptophan rotamer toggle switch because no change of the rotamer was observed in structures of activated receptors. The 
global toggle switch suggested earlier consisting of a vertical rigid motion of TM6, seems also to be implausible based on the recent 
crystal structures of GPCRs with agonists. Theoretical and experimental methods (crystallography, NMR, specific spectroscopic methods 
like FRET/BRET but also single-molecule-force-spectroscopy) are currently used to study the effect of ligands on the receptor structure, 
location of stable structural segments/domains of GPCRs, and to answer the still open question on how ligands are binding: either via 
ensemble of conformational receptor states or rather via induced fit mechanisms. On the other hand the structural investigations of homo- 
and heterodimers and higher oligomers revealed the mechanism of allosteric signal transmission and receptor activation that could lead to 
design highly effective and selective allosteric or ago-allosteric drugs.  
Keywords: 3-7 lock, 7TM receptors, allosteric, conserved motifs, dimerization, drug design, G-protein-coupled receptors, GPCRs, ionic lock, 
membrane receptors, molecular switches, receptor activation, signal transduction, transmission switch, tyrosine toggle switch.  
1. INTRODUCTION 
It is estimated that GPCRs are targets for about 50% of drugs 
currently on the market [1], mainly due to their involvement in 
signaling pathways related to many diseases i.e. mental [2, 3], 
metabolic [4] including endocrinological disorders [5, 6], 
immunological [7] including viral infections [8, 9], cardiovascular 
[7, 10], inflammatory [11], senses disorders [12] and cancer [13]. 
The long ago discovered association between GPCRs and many 
endogenous and exogenous substances, resulting in e.g. analgesia, 
is another dynamically developing field of the pharmaceutical 
research [14].  
With the determination of the first structure of the complex 
between a G-protein coupled receptor (GPCR) and a G-protein 
trimer (G) in 2011 [15, 16] a new chapter of GPCR research 
was opened for structural investigations of global switches with 
more than one protein being investigated. The previous 
breakthroughs involved determination of the crystal structure of the 
first GPCR, rhodopsin, in 2000 [17] and the crystal structure of the 
first GPCR with a diffusible ligand (2AR) in 2007 [18]. How the 
seven transmembrane helices of a GPCR are arranged into a bundle 
was suspected based on the low-resolution model of frog rhodopsin 
from cryo-electron microscopy studies of the two-dimensional 
crystals [19]. The crystal structure of rhodopsin, that came up three 
years later, was not a surprise apart from the presence of an 
additional cytoplasmic helix H8 and a precise location of a loop 
covering retinal binding site. However, it provided a scaffold which 
was hoped to be a universal template for homology modeling and 
drug design for other GPCRs – a notion that proved to be too 
optimistic. Seven years later, the crystallization of 2-adrenergic 
receptor (2AR) with a diffusible ligand brought surprising results 
because it revealed quite a different shape of the receptor 
extracellular side than that of rhodopsin. This area is important 
because it is responsible for the ligand binding and is targeted by 
many drugs. Moreover, the ligand binding site was much more 
spacious than in the rhodopsin structure and was open to the 
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exterior. In the other receptors crystallized shortly afterwards the 
binding side was even more easily accessible to the ligand. New 
structures complemented with biochemical investigations 
uncovered mechanisms of action of molecular switches which 
modulate the structure of the receptor leading to activation states 
for agonists or to complete or partial inactivation states for inverse 
agonists.  
In this review we will describe the proposed activation 
mechanisms together with molecular switches, compare them and 
try to generalize the findings with respect to the other GPCRs not 
only from family A (the most populated Rhodopsin-like family) but 
also other families of these mysterious receptors. The action of 
molecular switches was most extensively investigated in the case of 
two types of receptors: rhodopsin and the -adrenergic receptors. 
The recent reviews on activation and action of molecular switches 
in the Rhodopsin family of GPCRs were published in 2009 by 
Ahuja and Smith [20], Nygaard et al. [21] and also by Hofmann et 
al. [22]. Some other reviews on activation mechanisms were 
published earlier by Strange [23] and recently by Deupi and 
Standfuss [24]. The two-year period since 2009 has been very 
fruitful for the GPCR research and provided detailed explanations 
on how some of the switches work as well as redefined some 
hypotheses in this field. In a very recent review [25] Unal and 
Karnik tried to generalize the concept of molecular switches and 
came to the idea of a coordinated domain coupling in GPCRs which 
could be a consequence of the dynamic nature of these receptors. 
According to this hypothesis when a ligand is bound to a receptor 
extracellular domain a decrease in the intrinsic disorder of this 
domain cooperatively changes the conformation of the neighboring 
receptor domain. Certainly, some other original concepts will be 
emerging based on the still growing number of crystal structures 
and other data associated with GPCRs and their complexes.  
2. SUPERFAMILY OF GPCRs 
The superfamily of G-protein coupled receptors (GPCRs) can 
be divided into five main families: Glutamate, Rhodopsin, 
Adhesion, Frizzled/Taste2 (consisting of frizzled, smoothened and 
taste2 receptors), and Secretin, according to the GRAFS 
classification system [26] which displaced the previous A-F system Molecular Switches in GPCRs  Current Medicinal Chemistry,  2012 Vol. 19, No. 8      1091 
[27, 28]. The GRAFS system was formed using the Hidden Markov 
Model approach to analysis of multiple sequence alignments of all 
GPCRs from 13 eukaryotic genomes. All five families were formed 
in the early stage of metazoan evolution and the number of GPCRs 
in each family increased during evolution. At present, sequence 
diversity of GPCRs and their abundance is enormous, giving 
organisms more ways to adapt to various environmental conditions 
[29]. Additionally, the Rhodopsin family, the largest and the best 
described of all, is divided into four groups: , ,  and , out of 
which only the  group does not have any representative in the PDB 
database. The above internal classification of the Rhodopsin family 
is still under discussion as other methods such as NJ (Neighbor-
joining) or UPGMA (Unweighted Pair Group Method with 
Arithmetic mean) provided phylogenetic trees of a different fan-like 
shape [30, 31]. Lately, using the multidimensional scaling (MDS), a 
non-phylogenetic statistical method adapted to evolutionary distant 
sequences, Chabbert and co-workers [32] showed that the 
Rhodopsin family should be divided into 4 groups. The central 
group, G0, is formed by peptide receptors, opsins and melatonin 
receptors. The second group, G1, includes somatostatin and opioid 
receptors, chemokine and purinergic receptors, proteinase activated 
receptors and acid receptors. The G2 group is formed by biogenic 
amine receptors and adenosine receptors. Finally, the G3 group 
consists of receptors for melanocortin, phospholipids and 
cannabinoids, glycoprotein hormone receptors and leucine-rich 
repeat (LRR) containing receptors, prostaglandin receptors and 
Mas-related receptors. This classification of Rhodopsin GPCRs 
emphasized the role of proline residues patterns in TM2 
(transmembrane helix 2) and TM5 (observed in correlated 
mutations) which was confirmed by the recently solved CXCR4 
structure [33].  
Despite the large sequence diversity, all GPCRs most probably 
share the same fold: seven transmembrane helices joined by 
extracellular and intracellular loops of varied length (see Fig. (1)). 
A 7TM core is well preserved in all known to date protein 
structures of GPCRs despite the high degree of sequence variability 
within this region. It is worth noticing that the seven helix bundle is 
not a unique feature of G-protein coupled receptors, since there are 
other proteins in eukaryotic and prokaryotic organisms which share 
this fold. For example in eukaryotes, a 7TM fold appears in high-
conductance Ca
2+-activated potassium channels (BKCa) [34] and in 
ligand-gated ion channels [35] which do not have any evolutionary 
relationship with GPCRs. Particularly, in prokaryotes, light-induced 
structural changes in the 7TM core of bacteriorhodopsin [36, 37] or 
halorhodopsin [38] provoke pumping of protons (hydrogen ions) or 
halide ions, respectively, through the membrane, or induce protein-
protein interactions which initiate a signaling cascade associated 
with phototaxis, as in the case of the sensory rhodopsin I-transducer 
complex [39]. 
While the 7TM core is a typical common feature of GPCRs, the 
extracellular and intracellular regions differ in structure, sequence 
and length allowing interactions with various signaling molecules 
and ligands: ions, organic odorants, amines, peptides, proteins, 
lipids, nucleotides and photons [26]. Moreover, many GPCRs, so-
called orphan receptors, still lack a reliable assignment of 
interacting ligands and some of them may not even need ligands for 
activation but, most probably, are self-activated through 
heterodimerization [40]. In general, ligands bind to the extracellular 
loops and the N-terminus, while the intercellular part of GPCRs is 
involved in protein-protein interactions with G proteins, arrestin or 
other subunits. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). General scheme of topology and location of conserved residues in Rhodopsin-like GPCRs. Number of residues and their locations in each TM is 
based on chemokine receptor CXCR4 (H8 is not present in the crystal structure so it is shown transparent). Residues in bold are the most conserved in each 
TM. Sequence motifs are shown as gray areas. An alternative position of proline residue in TM2 is denoted by (P). Detailed description of figure is done in 
main text. 1092    Current Medicinal Chemistry,  2012 Vol. 19, No. 8  Trzaskowski et al. 
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Depending on the GPCR family different regions of receptors 
are involved in the activation process (see Table 1). The common 
role of GPCRs is a signal transmission to the cell interior through 
interactions with molecules, such as the G protein or arrestin, by 
changing the structure of their transmembrane domains and/or 
extracellular and intracellular parts after the ligand binding. G 
protein-coupled signal transduction involves dissociation of G 
protein into G and G subunits which modulate enzymes or 
membrane channels leading to a highly amplified signaling cascade. 
In the absence of any ligand a G-protein coupled receptor is 
believed to be in a dynamical equilibrium between the inactive (R) 
and the less populated active (R*) state. Binding of an agonist 
molecule (full or partial) is thought to increase the probability of the 
receptor converting to R* [41]. Such a scheme is preferred in the 
case of GPCRs with diffusible ligands, however, in the case of 
rhodopsin, endowed with a very tight ligand binding site, probably 
the induced fit mechanism is employed [42]. It is possible that in 
most GPCRs both mechanisms are operational but in different 
proportions. These two types of activation paths, the dynamic 
equilibrium of receptor states and the agonist-induced 
conformational change, will be described in detail later on. 
Antagonists prevent the binding of both agonists and inverse 
agonists into the orthosteric site (a binding site for endogenous 
agonists) but they can also change the receptor structure (or choose 
a particular state of the receptor according to ensemble of 
conformational receptor states) which can even induce receptor 
internalization in some cases. GPCRs activation and signal 
transmission can also be influenced by allosteric or ago-allosteric 
modulations induced not only by several ligands known to date [43, 
44] but also through either negative or positive cooperation between 
protomers within a dimer. Many functional studies proved 
dimerization of GPCRs [45] although even a monomer is able to 
activate its G protein [46], to bind arrestin or to undergo 
phosphorylation catalyzed by GRKs (GPCR kinases) [47]. The role 
of oligomerization in activation and signal transduction by GPCRs 
is still not clear although some experimental and theoretical studies 
involving not only Rhodopsin but also the Glutamate and Secretin 
families proved its relevance [48, 49]. Moreover, many GPCRs, so-
called orphan receptors, still lack reliable assignment of interacting 
ligands and some of them are probably self-activated i.a. through 
heterodimerization [40].  
GPCRs were traditionally considered to be monomeric and 
recent studies of GPCRs reconstituted in high-density lipoprotein 
particles have confirmed that these receptors can exist and function 
as monomers [46, 50]. However, as evidenced by biochemical 
measurements of cooperativity, biophysical determinations of 
fluorescence or by bioluminescence resonance energy transfer 
between protomers, co-immunoprecipitation and other methods 
GPCRs from various families can assemble as dimers or higher-
order oligomers [51-53]. Currently, dimerization was proposed to 
play a role in processes ranging from ligand binding to receptor 
signaling, maturation, trafficking and regulation. For the glutamate 
receptor family of GPCRs activation involves a movement of the 
N-terminal Venus flytrap domain (VFTD) within a dimeric GPCR 
entity to activate the membranous domains, which suggests that 
dimerization is mandatory for agonist-induced activation [54]. It is 
likely that various allosteric interactions between monomers in an 
oligomeric complex represent those that occur between distinct 
sites within a given GPCR monomer [55]. To date, experimental 
data suggest that GPCR dimers and oligomers are functionally 
asymmetric which was characterized especially for GABABR and 
the mGluR receptors from the glutamate family [56, 57]. Because 
of asymmetric functionality the subunits in a GPCR dimer possibly 
adopt different conformations in a particular receptor state (inactive 
or active). Recent studies on dopamine D2 receptor dimers have 
also demonstrated asymmetric communication between an agonist-
bound and an antagonist-bound protomers within the D2 dimer 
[53]. 
Homo- and hetero-dimerization can modulate the signaling 
properties of receptors and mediate cross-talk between GPCR 
pathways [58]. Crystal structures can also directly suggest novel 
allosteric sites with specific properties and selectivity. For example, 
a cholesterol binding site located in the interface between protomers 
consisting of helices TM1 and H8, has been observed in many 
dimeric 2-adrenergic receptor crystal structures [59]. Cholesterol 
can modulate receptor thermostability and ligand affinities. 
However, even for the most studied dimers the identification of the 
functionally relevant interface is still very difficult. This is partly 
due to the transient mode of the interactions and the technical 
problems of differentiating between specific and nonspecific 
binding in membrane environment [60]. On the other hand, it was 
observed in crystallization studies that nonspecific or partial 
dimerization of GPCRs can prevent crystal formation because it 
introduces heterogeneity to the system, so it is usually avoided. 
Therefore, in most crystal structures of GPCRs analyzed so far the 
receptor molecules have been found in non-functional (antiparallel 
or tilting) orientations. The recent crystal structures of CXCR4 [33] 
are rather exceptions revealing a parallel dimer arrangement 
involving helices TM5 and TM6. The dimer interface is virtually 
identical in five different crystal packing forms of CXCR4 with 
both peptide and small-molecule antagonist, which can suggest that 
it is functionally relevant [61]). 
Using a fluorescence resonance energy transfer (FRET) to 
characterize the oligomerization of 2AR Fung et al. [52] proposed 
that  2AR forms predominantly tetramers when reconstituted in 
phospholipid vesicles. Agonists and antagonists had little effect on 
the relative orientation of protomers in the oligomeric complexes so 
it was suggested that the tetramer structure is loose enough to 
accommodate a large, outward movement of the cytoplasmic part of 
TM6. In contrast, binding of inverse agonists led to a significant 
increase in FRET efficiencies for most labeled amino acid pairs. 
This could suggest that inverse agonists can induce tighter packing 
of protomers and/or stimulate the formation of larger oligomers 
(possibly octamers or larger structures) by employing the additional 
interface at the receptor surface. The results provide new insights 
into 2AR oligomerization and reveal a possible mechanism for the 
functional effects of inverse agonists. The interface involving 
helices TM1 and H8 was proposed for a symmetrical dimer (as it 
was found in the crystal structures of this receptor type) so the 
tetramer would be a dimer of dimers. Upon binding of an inverse 
agonist the dimers could form a tighter structure and additionally 
the tetramers could stick together to form octamer engaging an 
interface involving helices TM4 and TM5. In this way a larger 
oligomer can be formed using more tetramers. Similar interfaces 
were proposed for rhodopsin oligomers based on the AFM 
measurement [62, 63], however in this case the interface in a 
rhodopsin dimer involved helices TM4 and TM5 while contacts 
between rows of dimers were maintained by helices TM1 from 
different protomers.  
3. MECHANISMS OF MOLECULAR ACTIVATION 
The idea of a common molecular activation mechanism in G 
protein-coupled receptors (GPCRs) has been developed in the late 
80's based on the structural homology of GPCRs. Despite the 
wealth of different classes of molecules activating GPCRs it was 
believed that the activation of all GPCRs utilizes a similar 
mechanism which triggers the response through a common set of G 
proteins. Several experiments from the early 90's showed, however, 
that there is probably no common "lock" for all the members of the 
GPCR family [64-66]. Molecular switches can be precisely 
observed in the already solved structures of GPCRs (Fig. (2)). 
However, to search for such strong inter-residue interactions which 
stabilize either the active or inactive states in GPCRs of unknown 
3D structure some sophisticated experimental or theoretical 
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conserved (e.g. in the Rhodopsin family). Consequently, multiple 
sequence alignments and homology modeling combined with 
molecular dynamics (MD) simulations are often used to capture 
novel stabilizing interactions especially in GPCRs families other 
than Rhodopsin. 
3.1. Glutamate Receptors 
The glutamate receptors (previously: class C of GPCRs) are 
activated through binding of a ligand by a well-conserved so-called 
“Venus flytrap module” (VFTM) in the N-terminal region 
consisting of two lobes [67]. Structural changes induced by agonist 
binding (the closure of lobes) are propagated from the VFTM 
domain through conserved disulphide bridges within the 
extracellular cysteine-rich domain (CRD) to the TM core (see Table 
1) [68]. GABA-binding GPCRs from the Glutamate family share 
also an additional common domain in the N-terminal region: 
SUSHI (also known as complement control protein modules or 
short consensus repeats) [69]. Studies on mGlu receptors showed 
that the simultaneous closure of lobes in the VFTM domain of both 
protomers in a dimer during activation by an agonist is necessary to 
maintain the high binding affinity towards the G protein [48]. This 
suggests that dimerization is a required step for the full 
performance of Glutamate GPCRs. Glutamate receptors are targets 
not only for endogenous orthosteric ligands but also for many 
specific allosteric modulators found to date that interact with TM3, 
TM5, TM6 and TM7 which are more diverse in sequence than the 
well-conserved N-terminal region [70]. Due to this considerable 
sequence diversity in the TM region allosteric ligands, PAMs 
(positive allosteric modulators) or NAMs (negative allosteric 
modulators), can be more selective than the orthosteric ones. Most 
importantly though, HTS (High-Throughput Screening) and the hit 
optimization of these allosteric ligands combined with the 
Rhodopsin-based homology modeling and mutagenesis, provided 
important insights into molecular switches present in Glutamate 
GPCRs [71], which would not otherwise be possible because of the 
lack of any representative 3D structure of this receptor family. It 
was shown that the conformational movement of TM6 with respect 
to TM3 during the activation process in the mGlu5 receptor could 
be inhibited by MPEP (NAM) which interacts with aromatic 
residues in TM3 and TM6 [72, 73] and Ser and Ala in TM7 [74]. 
Quite often, switching from the PAM to NAM ligands targeting 
mGlu receptors can be done with very subtle changes of a ligand 
chemotype, e.g. replacement of fluorine with chlorine atom or 
fluorine with methyl group (e.g. in analogs of ADX47273) [71]. 
Such changes would not be of much consequence in the case of 
orthosteric ligands. The sequence analysis [69] pointed to some 
weakly conserved motifs in TM6 and TM7 of Glutamate GPCRs 
(see Table 1) which could be involved in activation, i.e. ‘wl’ 
aligning with the Rhodopsin family CwxP motif and ‘pkxy’ which 
could act similarly to ‘nPxxy’ in the Rhodopsin-like receptors. 
Uppercase letters in the motifs indicate completely conserved 
positions, lowercase indicate well-conserved positions (>50%) and 
x indicates any amino acid. 
3.2. Adhesion Receptors 
The Adhesion family (previousely: class B), for which 
endogenous ligands have not been identified so far, lacks a 
complete description of the common activation process. Based on 
the recent findings on the GPR56 protein, however, it is suggested 
that a G-protein is involved in signal transduction by this family of 
receptors [75]. Although conserved polar and aliphatic residues 
which could be involved in the activation mechanism are present in 
helices TM3, TM4 and TM6 (see Table 1) the typical signature of 
Adhesion GPCRs are highly O- and S-glycosylated long N-termini 
with the cxCxhlt/s motif inside the GPS domain involved in an 
autocatalytic proteolytic process. The sequence diversity of the 
Adhesion family is significant, particularly in the N-terminal 
region, although some cysteine residues are well-conserved also in 
the TM core. 
3.3. Secretin Receptors 
A long cysteine-rich N-terminal region with a ligand-binding 
site (HBD - a hormone-binding domain) is also a typical feature of 
the Secretin family (previously: class B) but without the presence of 
a proteolytic domain like in Adhesion receptors. The common 
motifs including cysteins located in N-termini are 
CnxxwDxxxxCW and rxCxxxGxw (see Table 1). In this review we 
decided to use the following nomenclature [76]: uppercase letters in 
the motifs indicate completely conserved positions, lowercase 
indicate well-conserved positions (>50%) and x indicates any, non-
conserved amino acid. The active conformation of the receptor is 
stabilized by simultaneous interactions of the ligand with the N-
terminus, extracellular loops and TM6 [77, 78]. Neumann et al. 
proposed that the motif crucial for class B receptors activation is 
located in the N-terminal helix cap where it interacts with the 
peptide ligand which forms a well-defined helix upon binding to a 
receptor [79]. 
3.4. Frizzled Receptors 
The most conserved among all GPCRs [29] Frizzled-like 
receptors contain the N-terminal cystein-bridged ligand-binding 
region which is involved in the interaction with Wnt glycoproteins. 
Smoothened receptors belonging to the same family transmit 
signals through G proteins in a ligand-independent manner as a part 
of the sonic hedgehog-smoothened complex [80]. In both the 
Frizzzled and Smoothened receptors conserved cysteine bridges 
between extracellular loops are indispensable for the proper 
functioning of receptors but in Taste2 receptors, belonging to the 
same family, different crucial residues are present in EC1 and EC2 
loops, i.a. the NxWaVtnH motif in EC1 loop (see Table 1) [81]. 
Recently, Xenopus Fzd3 (Frizzled-like) was found to be functional 
as a homodimer in transduction of the Wnt/-catenin signal [82]. 
4. EXPERIMENTAL METHODS TO PROBE ACTIVATION 
OF RHODOPSIN FAMILY OF GPCRs 
4.1. Crystal Structures of Rhodopsin and Opsin 
The development of crystallographic and spectroscopic 
techniques in recent years allowed researchers to study in details 
the activation mechanism of GPCRs. In this section we will 
describe advances in the techniques and their relevance for 
investigations of GPCR activation while in Table 2 we provide 
information about all available crystal structures of GPCRs 
including the type of a ligand, its name, PDB id, resolution and 
references to the literature. In 2004 two new structures of bovine 
rhodopsin were published. First, Okada et al. used new 
crystallization conditions to obtain a full structure of the protein, 
with no gaps present, at a very accurate, 2.2 Å resolution [83]. Such 
a good accuracy gave an insight into a chromophore structure, 
showing e.g. the expected configuration about the C6-C7 single 
bond and a twist around the C11-C12 double bond. In another work 
Li  et al. solved the structure of bovine rhodopsin in a trigonal, 
rather than tetragonal, crystal form [84]. It was interesting to note 
that even though the packing of rhodopsin molecules in crystals 
was different, only very minor differences in atom coordinates were 
present. On the other hand the latter structure helped to solve the 
positions of all the remaining internal water molecules, which were 
further stabilizing rhodopsin structure via formation of extensive 
hydrogen-bond networks. Other similar studies confirmed the 
overall structure of rhodopsin [85, 86]. These studies, while 
providing a milestone for GPCR structure understanding, gave a 
rather poor insight into the activation mechanism of GPCRs since 
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In 2006, however, three different groups performed 
experiments aiming at elucidation of the rhodopsin structure in 
different states. First, Nakamichi and Okada studied the differences 
between rhodopsin and bathorhodopsin using X-ray crystallography 
under cryogenic conditions with and without  illumination [87]. 
They found some differences in electron densities for these two 
states, which concerned mostly the retinal molecule, but were 
relatively small for the residues interacting with it. The same 
authors managed also to trap rhodopsin in the lumi phase, by 
illuminating and then successively warming the bathorhodopsin 
system [87]. In this case they were able to notice a nearly complete 
all-trans conformation of retinal as well as much larger differences 
in orientations of side chains of the selected residues. They were 
also able to observe small distortions of the TM3 backbone and 
changes in the interactions of this helix with TM2 and TM6. 
Photoactivated rhodopsin was also studied in the work of Salom et 
al. but the resulting crystals were obtained only at the 4.2 Å 
resolution [88]. Due to low accuracy the authors were able to spot 
differences between this structure and the ground-state rhodopsin 
only in portions of the cytoplasmic loops and in the position of 
retinal in the binding pocket. Both groups concluded that the 
changes in electron densities between rhodopsin and lumirhodopsin 
were not as large as expected, particularly for TM6. 
A true insight into the active state of rhodopsin became possible 
in 2008, after Park et al. determined the crystal structure of opsin, 
the first ligand-free form of a GPCR [89]. In general, ligand-free 
Table 2.  Summary of All Available Crystal Structures of GPCRs (Based on [61]) 
 
GPCR  Engineered  Type of ligand  Ligand name  PDB ID (Resolution Å) [Reference] 
A2AR (human)  IC3 fusion  Agonist  UK-432097  3QAK (2.71) [101] 
    Inverse agonist  ZM241385  3EML (2.6) [98] 
 Point  mutations  Agonist  Adenosine  2YDO (3.0) [105] 
    Agonist  NECA  2YDV (2.6) [105] 
    Antagonist  Caffeine  3RFM (3.60) [106] 
    Antagonist  XAC  3REY (3.31) [106] 
    Inverse agonist  ZM241385  3PWH (3.30) [106] 
1AR (turkey)  Point mutations  Agonist  Carmoterol  2Y02 (2.6) [104] 
    Agonist  Isoprenaline  2Y03 (2.85] [104] 
   Antagonist  Cyanopindolol  2VT4 (2.7) [74], 2YCX (3.25) [159], 2YCY (3.15) [159], 2YCZ 
(3.65) [159] 
    Inverse agonist  Carazolol  2YCW (3.0) [159] 
    Partial agonist  Dobutamine  2Y00 (2.5) [104], 2Y01 (2.6) [104] 
    Partial agonist  Salbutamol  2Y04 (3.05) [104] 
2AR (human)  IC3 fusion  Agonist  BI-167107, nanobody  3P0G (3.5) [96] 
    Agonist  FAUC50  3PDS (3.5) [96] 
    Antagonist  Alprenolol  3NYA (3.16) [97] 
    Inverse agonist  Carazolol  2RH1 (2.4) [18] 
    Inverse agonist  Compound #1  3NY9 (2.84) [97] 
    Inverse agonist  ICI118551  3NY8 (2.84 [97] 
    Inverse agonist  Timolol  3DS4 (2.8) [59] 
    Inverse agonist  FAB, not resolved  2R4R (3,4) [96], 2R4S (3.4) [96] 
    Inverse agonist  FAB, not resolved  3KJ6 (3.4) [135] 
  N-terminal fusion  Agonist  BI-167107, G, nanobody  3SN6 (3.2) [15] 
CXCR4 (human)  IC3 fusion  Antagonist  CVX15 peptide  3OE0 (2.9) [33] 
   Antagonist  Molecule  1t  3ODU (2.5) [33], 3OE6 (3.2) [33], 3OE8 (3.1) [33], 3OE9 (3.1) 
[33] 
D3R (human)  IC3 fusion  Antagonist  Eticlopride  3PBL (2.89) [99] 
H1R (human)  IC3 fusion  Inverse agonist  Doxepin  3RZE (3.1) [100] 
Opsin        3CAP (2.9) [89] 
     G  peptide  3DQB (3.2) [91] 
Rhodopsin (bovine)    Agonist  All-trans-retinal  2G87 (2.6) [139], 2HPY (2.8) [139] 
   Inverse  agonist  11-cis-retinal  1F88 (2.8) [17], 1U19 (2.2) [83], 1GZM (2.65) [83], L9H (2.6) 
[83], 1HZX (2.8) [83], 2I37 (4.0) [83], 3OAX (2.6) [83], 3C9L 
(2.65) [83] 
 Point  mutations  Agonist  11-trans-retinal, G peptide  2X72 (3.0) [122], 3PQR (2.85) [123], 3PXO (3.0) [123] 
     9-cis-retinal  2PED (2.95) [85] 
        2J4Y (3.4) [83], 3C9M (3.4) [83] 
Rhodopsin (squid)    Inverse agonist  11-cis-retinal  2ZIY (3.7) [86] 1096    Current Medicinal Chemistry,  2012 Vol. 19, No. 8  Trzaskowski et al. 
GPCRs are extremely difficult to purify, and in the case of opsin it 
was known that it is unstable and tends to aggregate. In this case 
solubilized opsin was crystallized by hanging-drop vapor diffusion, 
and the obtained crystals were cryoprotected and frozen in liquid 
nitrogen for X-ray analysis. The comparison between opsin and 
rhodopsin structures revealed that the TM1-TM4 core remains 
stable upon activation. On the other hand large changes were 
observed for the TM5-TM7 region, helix H8 and cytoplasmic loops 
IC2 and IC3. TM5 is about two helical turns longer than in 
rhodopsin and tilted in such a way that its cytoplasmic end shifts 
towards TM6. The cytoplasmic end of TM6 is tilted outward from 
the helix bundle and closer to TM5. The Arg3.50–Glu6.30 ionic 
lock is broken as was expected, but other interactions are formed 
(Arg3.50 interacts with residues on TM5, while Glu6.30 forms 
hydrogen bonds with residues on TM5 and TM6, see Fig. (2G)). 
The residues are numbered according to the Ballesteros-Weinstein 
numbering scheme: every amino acid identifier starts with the helix 
number, followed by the position relative to a reference residue 
being the most conserved amino acid in that helix which bears 
number 50 [90]. The cytoplasmic end of TM7 is also rearranged by 
Tyr7.53 rotation to a position where it blocks TM6 from moving 
back towards TM3. Finally, in contrast to rhodopsin, the opsin 
structure shows two openings of the retinal-binding pocket: one 
between TM5 and TM6 and another between TM1 and TM7. This 
suggests different retinal entrance and exit routes during receptor 
activation. These findings were confirmed later in similar study by 
Scheerer [91]. 
Advances in crystallization and high-resolution X-ray 
techniques, which allowed researchers to study the details of 
rhodopsin system, could not unfortunately be easily transferred to 
other GPCRs. It has been observed that other membrane receptors, 
particularly those for diffusible hormones and neurotransmitters 
(e.g. adrenergic receptors) exhibit significant basal, agonist-
independent G protein activation [92, 93]. This basal activity has 
been associated with structural instability, suggesting that 
intramolecular interactions maintaining the receptor in the inactive 
state are also important for the structural integrity of these proteins 
[94, 95]. This results in difficulties in generating high-quality 
crystals of many GPCRs, for which alternative methods and 
techniques are needed.  
4.2. Structures of other GPCRs – Stabilization via T4L 
In 2007 Rasmussen et al. obtained a high-resolution (3.4 Å) 
crystal structure of 2AR using a new approach which included 
generation of a monoclonal antibody (Mab5) that binds to the third 
intracellular loop of the receptor [96]. Binding of this antibody does 
not alter agonist or antagonists binding affinities, therefore it was 
concluded that it should not significantly alter the structure of 
2AR. The Mab5-receptor complex with bound inverse agonist 
(carazolol) was stable enough to generate crystals of good quality. 
In the same year Cherezov et al. suggested a different modification 
in which 2AR was modified by inserting T4 lysozyme (T4L) in 
place of the third intracellular loop [18]. The engineered 2AR-T4L 
complex, again with carazolol, yielded a very stable structure that 
was solved and refined at 2.4 Å resolution. It was shown that the 
fused T4L is tilted away from the receptor and its interactions with 
the protein are minimal (only two salt bridges). It was also shown 
that there were no significant differences between this structure and 
the 2AR-Mab5 structure studied earlier, although the cytoplasmic 
end of TM6 was pulled outward in the former structure due to the 
interactions with T4L. Interestingly, both structures have the 
Arg3.50-Glu6.30 ionic lock broken, even though the residues that 
should be forming it are relatively close to each other (Fig. (2H)). 
The same T4L fusion technique has been used in the recent 
years to obtain more GPCR structures. In 2008 Hanson et al. used 
the same 2AR-T4L chimera to identify a specific cholesterol 
binding site within this receptor [59], while Wacker showed the 
binding modes of 2AR with antagonists and inverse agonists [97]. 
In the same year Jaakola et al. managed to obtain high-quality 
crystals (solved at 2.6 Å) of the human A2A adenosine receptor – 
T4L chimera bound to the ZM241385 antagonist [98]. Similarly to 
the 2AR case, this receptor does not have the ionic lock closed 
(Fig. (2I)). Instead, Asp3.49 forms a hydrogen bond with Tyr3.60 
in the IC2 loop while Arg3.50 interacts with Thr2.39 in TM2 
additionally restraining the helical conformation of IC2. It was 
suggested that in the case of the A2A adenosine receptor Arg3.50 
may play a role in stabilizing the deprotonated state of the adjacent 
Asp3.49 residue, which would strengthen the polar interaction 
between the (d/e)Ry motif, IC2 and TM2 with direct implications 
on G protein activation. It is also interesting to note that the 
antagonist is interacting with Trp6.48, even though it is bound in a 
completely different orientation than retinal in rhodopsin (along the 
main axis of the receptor, Fig. (2C)).  
The lysozyme-stabilization method has also been used recently 
to obtain crystal structures of the CXCR4 chemokine receptor [33], 
dopamine D3 receptor [99], histamine H1 receptor [100] with 
antagonists as well as the agonist-bound A2A adenosine receptor 
[101]. Of those structures, only the antagonist-D3R complex has the 
Arg3.50-Glu6.30 ionic lock not broken (analogous to Fig. (2G)). 
On the other hand the crystal structures demonstrated that even 
when the agonist is covalently bound to the receptor, the FAUC50-
2AR-T4L crystallizes in an inactive conformation – the ionic lock 
is broken but there is no movement of TM6 [102]. There were 
concerns whether lysozyme fusion alters the pharmacology and 
overall structure of GPCRs [18]. To answer this question an 
alternative approach for obtaining GPCR structures has been 
proposed. This method, called thermostabilization, involved 
introduction of a small number of point mutations into the receptor, 
which increase its thermostability and alter the equilibrium between 
agonists and antagonists conformations. 
4.3. Thermostabilization by Point Mutations 
The first success of this method came in 2008 when Warne et 
al. obtained a 2.8 Å resolution structure of 1AR [103]. This GPCR 
was even more challenging than the previously-crystallized 
membrane proteins, due to its spontaneous cycling between inactive 
and active states and overall low stability. Two thermostabilizing 
mutations, Cys116Leu and Cys358Ala, were introduced to the 
protein to alter its equilibrium so that the mutant receptor remains 
in the antagonist state. The resulting construct bound to an 
antagonist (cyanopindolol) gave high-quality crystals solved at the 
2.7 Å resolution. In this structure the Arg3.50–Glu6.30 ionic lock is 
broken, and instead Asp3.49, Arg3.50 and Tyr3.51 are involved in 
interactions with intracellular loop 2 (similarly to the structure of 
adenosine A2AR with antagonist [98]). The same group also 
obtained crystal structures of the same construct bound to four 
different agonists: R-isoprenaline, R,R-carmoterol, R-salbutamol 
and R-dobutamine [104]. Interestingly, the overall structures of all 
agonist-bound systems were very similar to the antagonist-bound 
one and none of the structures showed the expected movement of 
TM6 which was observed during photoactivation of rhodopsin. The 
major differences were noticed in the binding pocket, where 
Ser5.43 and Ser5.46 had different rotamer conformations than in 
the antagonist-bound form. Authors concluded that agonist-bound 
crystal structures represent an inactive state of the receptor formed 
during initial agonist binding. 
The thermostabilization method gave, however, even more 
insight into GPCR activation when applied to the A2A adenosine 
receptor. First, Lebon et al. used four point mutations (L48A, 
A54L, T65A and Q89A) to obtain a stable receptor bound to two 
different agonists, adenosine and NECA [105]. Both ligands bind to 
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earlier for the antagonist binding to the A2A-T4L chimera. The 
relative similarity of the whole structure to the A2A-T4L structure 
suggests that it is only a partially activated state of the receptor. The 
largest deviations from the antagonist-bound structure have been 
found for TM3 (shifted by 2 Å) and in the conformation of the 
cytoplasmic ends of helices TM5-TM7. The extent of these changes 
was, however, much lower than the changes occurring upon 
rhodopsin activation to opsin. Recent crystal structures of the A2A 
receptor, which have been obtained both in agonist-bound [98, 105] 
and antagonist-bound states [106, 107], allowed the GPCR 
community to obtain another interesting clue concerning receptor 
activation. Similarly to the 2AR case, ligand binding causes small 
conformational changes within the ligand cavity which are different 
for different types of ligands. These changes, which include the 
already known TM6 and TM7 tilting and TM5 movement, change 
the intracellular interface of the receptor which facilitates binding 
of G proteins. The Arg3.50-Glu6.30 ionic lock is present in one of 
the antagonist-bound structures, but broken in the agonist-bound 
systems (Fig. (2)). 
Recently, Dore et al. have used the same technique to obtain 
A2A adenosine receptor crystals bound to three different 
antagonists, XAC, caffeine and ZM241385 [106]. In this case, 
however, a different set of stabilizing mutations (A54L, T88A, 
K122A, V239A, R107A, L202A, L235A, S277A) was chosen. The 
latter structure (A2AR bound to ZM241385) is particularly 
interesting, since it allows one to compare exactly the same system 
obtained using two different methods, thermostabilization and T4L-
fusion. The structures are, as expected, similar, raising confidence 
that both methods provide an effective approach to GPCR 
crystallization and do not result in major structural abnormalities. 
There is still a small chance that crystallization itself may introduce 
some unnatural structural features, but a good agreement between 
GPCR structures and their chemistry makes it rather unlikely. There 
are, however, some differences in TM5 and TM6, which are 
interesting from the structural point of view. TM5 has its C-
terminal part moved away from TM6, with respect to the A2AR-T4L 
structure, and TM6 has rotated away from TM5. This results in the 
presence of the Arg3.50-Glu6.30 ionic lock, which is in a similar 
conformation as in the rhodopsin structure. Some additional 
differences in the binding pocket suggest that A2AR structures with 
bound ZM241385, obtained using different crystallization methods, 
show, in fact, the protein in different conformational states. On the 
other hand, it was shown that the effect of T4L fusion is specific, 
since in the D3R-T4L structure the ionic lock was present. 
4.4. Nanobody and G Protein Facilitate Agonist Binding 
Recently, the crystal structure of a GPCR has also been 
obtained using a slightly different crystallization approach. In 2011 
Rasmussen et al. used a recombinant minimal-sized intact antigen-
binding domain of a camelid heavy chain antibody, called 
nanobody, to stabilize the 2AR-T4L structure bound to the BI-
167107 agonist [108]. It was found that the nanobody exhibits a G 
protein-like behavior, promoting activation of the GPCR. The 
resulting, 3.5 Å structure, represents the protein in the active state, 
with TM5 and TM6 displaced and TM3 and TM7 moved inward 
with respect to the inactive 2AR-T4L-carazolol structure. The 
largest change upon activation occurs at TM6, which shows a 11.4 
Å movement of Glu6.30, caused by a clockwise rotation of TM6 
close to the conserved Pro6.50. Also, the salt bridge between 
Asp3.49 and Arg3.50 is broken. These changes are almost identical 
to the changes caused by rhodopsin activation to opsin. On the 
other hand, the changes in the binding site of 2AR upon activation 
are rather subtle and centered around Ser5.46 in TM5. These 
changes are, however, propagated to other parts of the protein, 
rearranging the hydrogen bond network and, in turn, causing 
relatively large movements and rotations of helices. 
Very recently a 3.2 Å structure of the 2AR complex with a 
heterotrimeric GTP binding protein (Gs), a first high-resolution 
view of transmembrane signaling by a GPCR, was obtained [96]. A 
stable 2AR-Gs system was prepared by mixing the purified GDP-
Gs with a molar excess of 2AR, stabilized by both T4L and a new 
nanobody, and bound to the BI-167107 agonist. Later, GDP 
released from Gs was hydrolyzed and the complex was purified by 
different types of chromatographies. The largest difference between 
the G protein-coupled structure and the carazolol-bound inactive 
structure of 2AR is the 14 Å outward movement o TM6 and a 
smaller outward movement of TM5. Overall, this structure is very 
similar to the active 2AR-T4L-nanobody structure described 
earlier, with the root mean square distance of approximately 0.6 Å. 
This result gives confidence that both experimental structures are 
correct and this method does not introduce any significant errors.  
4.5. Probing Stability by Mechanical Unfolding 
Activation of GPCRs which operates via  the action of 
molecular switches involves conformational changes of the protein. 
However, different parts of these receptors resist the motion in 
different ways depending on the number and the quality of 
interactions stabilizing particular protein fragments. Using AFM 
(Atomic Force Microscopy) and especially its variations: SMFS 
(Single Molecule Force Spectroscopy) and DFS (Dynamic Force 
Spectroscopy), it is possible to estimate the rigidity and other 
mechanical and kinetic parameters of stable structural segments. 
Both methods involve mechanical unfolding of the investigated 
proteins. The experiment starts with an attachment of a protein to a 
tip of a cantilever which is then retracted perpendicularly to the 
surface of a membrane bilayer. During unfolding the forces needed 
to break the interactions stabilizing the protein are recorded 
together with the elongation of the backbone. In SMFS the 
unfolding is performed with a constant loading rate (a product of 
speed and a spring constant) while the DFS method consists of a 
series of SMFS experiments over a broad range of loading rates. 
Up to now the mechanical unfolding experiments were 
performed on rhodopsin - the only GPCR with the entire structure 
known. Analysis of DFS results of pulling of rhodopsin starting 
from the N-terminus led to the determination of positions of the 
stable structural segments [109]. It was revealed that almost all such 
segments contain secondary structure elements: segment 1
st and 2
nd 
– N-terminus; 3
rd – TM1-IC1-TM2; 4
th – loop EC1; 5
th – TM3-IC2-
TM4-EC2; 6
th – TM5-IC3-part of TM6; 7
th – second part of TM6-
EC3-TM7; 8
th – H8; 9
th – C-terminus. Only the N-terminus and 
TM6 were divided into two separate segments. In the case of 
rhodopsin which lacks the disulfide bond Cys110-Cys187 a 
division into segments differs from that of wild type rhodopsin 
starting from the 5
th segment, as this covalent bond keeps two 
helixes and two loops tightly together [110]. A comparison of the 
determined segments with the most conserved residues within 
GPCRs showed that those residues (including highly conserved 
motifs (d/e)Ry and nPxxy among others) are placed inside the 
stable structural segments. Because their positions are less likely to 
be altered during small conformational changes they certainly favor 
the creation of key interactions crucial for the functionality of 
rhodopsin. The DFS experiment revealed that segments 5
th and 6
th 
have the highest rigidity compared to the rest of the rhodopsin 
segments. The mixed composition of the rigid and flexible 
segments around the retinal binding cavity can be explained by two 
roles they perform: maintaining inactive receptor state but also 
allowing for conformational changes during activation [111]. 
Additionally, the unfolding profiles (force-displacement F-D 
curves) and positions of stable segments of bovine and mouse 
rhodopsin proved to be very similar in spite of 23 different residues 
in their sequences. This may indicate that the network of molecular 
interactions stabilizing the inactive structure and the functional state 
(receptor switches) is largely conserved [109]. To reveal how 1098    Current Medicinal Chemistry,  2012 Vol. 19, No. 8  Trzaskowski et al. 
proteins are unfolded some theoretical calculations were also 
performed by Fanelli and Seeber [112] who investigated the 
influence of single point mutations on stability of rhodopsin. They 
applied Steered Molecular Dynamics (SMD) simulations to screen 
through 20 mutants linked to the autosomal dominant form of 
retinitis pigmentosa. Unfolding curves exhibited three force peaks, 
similarly to previous SMFS experiments but without details 
characteristic to those experiments, therefore, no significant 
differences in the unfolding pathways for different mutants were 
obtained. However, the unfolding speed in these simulations was 
about eight orders of magnitude higher than the experimental one 
so, possibly, similar investigations using a much lower unfolding 
speed could reproduce details of the F-D curves and reveal 
unfolding events as well as the role of molecular switches in 
keeping the structural segments of rhodopsin highly stable. 
5. SWITCHES IN RHODOPSIN-LIKE RECEPTORS  
The activation of GPCRs occurs most probably through series 
of conformational changes called molecular switches. The crystal 
structures enables the researchers to almost see them in action by 
comparing structures of the same receptors with agonists and 
antagonists (Fig. (2)). Based on the crystal structures we describe 
those molecular switches that are well characterized and proposed 
to work in most of GPCRs.  
5.1. The Ionic Lock Switch 
The presence of the first switch, the ionic lock, has been shown 
in the first GPCR X-ray structure obtained by Palczewski et al. 
[17]. The inactive state of bovine rhodopsin shows a strong 
intramolecular interaction between residues Glu3.49/Arg3.50 of the 
conserved (d/e)Ry motif in TM3 and residues Glu6.30/Thr6.34 in 
TM6 (Fig. (2G)). The authors of that paper concluded that "it could 
be one of the critical constraints keeping rhodopsin in the inactive 
occupation", but also noted that this region has high 
crystallographic B-values, meaning that the side chains may assume 
different conformations. Following that work as well as 
mutagenesis studies, which showed the importance of the (d/e)Ry 
motif [113], the activation mechanism of GPCRs has been 
described as a cascade of altering molecular switches in conserved 
microdomains [20, 114]. In this mechanism, ligand binding triggers 
a series of molecular switches (including the TM3-TM6 ionic lock) 
to unlock the G protein-binding site in the intracellular face of the 
receptor, leading to G protein activation. 
Apart from inactive rhodopsin there are only few crystal 
structures in which this particular ionic lock is observed. The 
dopamine D3 receptor [99] and adenosine A2A receptor [106] (but 
only with selected antagonists) are the only other GPCRs that show 
the Arg3.50-Glu6.30 ionic lock in the crystal structure. In addition, 
the residues Asp3.49 and Arg3.50 are forming hydrogen bonds with 
Tyr3.60 (located in IC2), possibly stabilizing the ionic lock and 
restraining a helical conformation of IC2. The turkey 1-AR 
structure has the ionic lock open but because of the close proximity 
of helices TM3 and TM6, the different rotamers of these residues 
would yield the switch closed. The AA2R-T4L chimera has a similar 
structure in this region and the (d/e)Ry motif is forming a Asp3.49-
Tyr3.60 hydrogen bond which restrains the conformation of 
intracellular loop 2 (IC2). In the human 2AR structure the ionic 
lock between Arg3.50 and Glu6.30 is absent; instead, a hydrogen 
bond between the highly conserved Tyr3.60 and His6.31 is present. 
CXCR4 is lacking the Glu6.30 residue and no ionic lock is present 
between TM3 and TM6. In the histamine H1 receptor the ionic lock 
is also absent; instead, Arg3.50 adopts a different conformer and 
forms a hydrogen bond with Gln6.36 in TM6 which can also bridge 
helices TM3 and TM6 to some extent. The lack of the ionic lock 
despite the presence of residues capable of forming strong 
interactions has been intriguing; some attribute it to the inclusion of 
the T4L fusion protein in crystal structures, which may affect the 
interactions in TM6. 
5.2. The 3-7 Lock Switch 
In rhodopsin the key restrain which is broken first upon retinal 
isomerization is a salt bridge between a protonated Schiff-base of 
retinal-Lys7.43 and a counterion, Glu3.28 (Fig. (2J)). This switch is 
called the 3-7 lock because a link between TM3 and TM7 is broken 
during activation. A similar mechanism probably exists in other 
receptors, especially with amine-type ligands (aminergic receptors) 
e.g. histamine H1 [100] or dopamine D3 [99], which were 
crystallized with antagonists bound and also in opioid receptors 
(OPR) for which an extensive modeling was done [115-120]. In 
these receptors the switch is composed of different residues: 
Tyr7.43 (which is more conserved than lysine present in rhodopsin) 
and Asp3.32 which substitutes for the rhodopsin’s counterion, 
Glu3.28. Asp3.32 is located on the same face of TM3 and deeper in 
the receptor interior which compensates for a shorter length of its 
side chain. In 1-  and  2-adrenergic receptors there is also a 
hydrogen bond, Asp3.32-Tyr7.43, but additionally, the Asn7.39 
residue, positioned one turn of helix away of Tyr7.43, is linked to 
Asp3.32 by a protonated nitrogen atom of aminergic receptor 
ligands. This is why disruption of the Asp3.32-Tyr7.43 hydrogen 
bond does not break the link between TM3 and TM7 so the 3-7 lock 
switch is not functioning in adrenergic receptors. Opening of the 3-
7 lock was suggested by Khorana [121] to be the first switch 
activated in rhodopsin and possibly it is one of the first switches 
that can be activated upon ligand binding in some other GPCRs. In 
Fig. (2) it is represented by one panel with rhodopsin structures.  
5.3. Transmission Switch (Former Trp Rotamer Toggle Switch) 
In all crystal structures with agonists there are movements of 
TM5 and TM6 but they vary considerably. Several similarities can 
be observed including a relocation of conserved residues Trp6.48 
and Phe6.44 towards Pro5.50 (Fig. (2A-C)). Such movements were 
called “a transmission switch” by Deupi and Standfuss [24] instead 
of the previous name “rotamer toggle switch”. This novel and larger 
switch links the agonist binding site with the movement of TM5 
and TM6 through rearrangement of the TM3-5-6 interface. This is 
possibly the most common switch among GPCRs. After movement 
of Trp6.48 in rhodopsin the Phe6.44 residue situated one helix turn 
away toward the cytoplasmic side of TM6, is displaced toward 
Leu5.51 as the whole TM6 is rotating horizontally. In -adrenergic 
receptors a little contraction of the binding site is observed while in 
rhodopsin isomerization of retinal makes the binding site much 
larger. The interaction of Ser5.42 and Ser5.46 with agonists 
stabilizes the receptor conformation which leads to a 2.1 Å 
movement of TM5 and about a 1.4 Å movement of Pro5.50 
whereas, unlike in rhodopsin, there is no movement of Trp6.48. 
However, there is a rotation and movement but only of the 
cytoplasmic part of TM6. This is translated to a relocation of 
Ile3.40 from its position at Pro5.50 and a motion of Phe6.44 due to 
rotation of TM6. Activation of this switch seems to be limited to 
some classes of GPCRs. Apart from these differences the activation 
mechanism of A2AR is similar to that of rhodopsin because Trp 6.48 
is also moved and TM6 rotated. There are also similar 
rearrangements in 2AR and rhodopsin in TM5 and TM6, by 
movements of Phe6.44 towards Pro5.50 and Leu5.51 together with 
the movement of Ile3.40 away from Pro5.50 – such translocations 
are part of the transmission switch. Agonist binding in A2AR results 
in the relocation of Ser7.42 and His7.43 which, together with 
Thr3.36 in TM3, coordinate a part of the agonist. These interactions 
resemble the 3-7 lock between the protonated Schiff base of the 
retinal-Lys7.43 and Glu3.28, which is critical for rhodopsin 
activation. Although the TM3-agonist-TM7 interactions in the 
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they could fulfill a similar role in arranging TM3 and TM7 in the 
active and inactive conformations [24]. 
The switches together with the hydrogen bond network between 
conserved residues, motifs and structural water molecules constitute 
an extended interface between different areas in GPCRs which 
facilitate the large movements linking ligand binding to cell 
signaling. Based on the recent crystal structures of inactive and 
activated, as well as constitutively active rhodopsin, one can 
elucidate the activation scheme of this protein and the role of 
particular switches as it was done by Standfuss et al. [122]. The 
structure of retinal in all-trans conformation, but unbound from 
Lys7.43, represents the active structure of rhodopsin nearly 
identical to the Meta-II state. This structure was published nearly 
simultaneously with the Meta-II rhodopsin structure with covalently 
bound retinal with and without GCT (C-terminus of G subunit) 
[123]. The structures agree with each other in location of the main 
conserved amino acids. A covalently bound all-trans retinal 
behaves as a full agonist, whereas when unbound, it behaves as a 
partial agonist but maintains the critical interactions between the -
ionone ring and helices TM5 and TM6. The structure of a 
constitutively active mutant Glu3.28Gln [122] represents probably 
a trapped intermediate when retinal is either entering or exiting the 
binding site. The transition from an inactive to active state of GPCR 
includes large rigid motion of TM6. In the case of rhodopsin this is 
not a vertical hinge movement (named a global toggle switch) but a 
horizontal (in plane of the membrane) rotation of TM6 that leaves 
the shape of the helix intact. The characteristic bend of TM6 is 
imposed by Pro6.50 which is a part of the CwxP motif. The other 
highly conserved amino acid, Trp6.48, is tightly packed against 
retinal in the ground state of rhodopsin as it has a central role in the 
transmission switch model (previously called a rotamer toggle 
switch) of activation of these receptor. The structure of the 
Glu3.28Gln mutant places this residue 3.6 Å from its ground state 
position. However, no rotamer change is observed as it was 
proposed based on biochemical experiments and also computer 
simulations. Instead, Trp6.48 follows the retinal (its -ionone ring) 
maintaining contact with the C18 methyl group.  
5.4. Tyrosine Toggle Switch (nPxxy Motif) 
A region called the hydrophobic barrier (Fig. (3A)) separates 
the water mediated hydrogen bond network from the (d/e)Ry motif 
which is critical for G protein activation (Fig. (2D-F)). In the active 
Glu3.28Gln-GCT structure, a rotation of TM6 disrupts the water 
mediated link between Trp6.48 and Ser7.45 and reorganizes the 
ground-state hydrogen bond network. The hydrophobic barrier 
opens and Tyr7.53 of the nPxxy motif, together with Tyr5.58, 
rearrange to fill the hydrophobic gap and to extend the hydrogen 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). The action of molecular switches in GPCRs. Four switches are shown: transmission switch, tyrosine toggle switch, ionic lock, and 3-7 lock. They are 
shown based on the crystal structures of rhodopsin, 2AR and A2AR with agonists and antagonists/inverse agonists. Their id numbers from Protein Data Bank 
are provided – first number for inactive and second for active receptor. Additionally, the structural formulas of agonists from the crystal structures of active 
receptors are shown. The general scheme of GPCR structure is shown based on the crystal structure of chemokine receptor CXCR4 with a small ligand. Blue 
arrows in circular panels indicate motions of receptor structure during action of particular switch. Inactive receptor structure is shown in gray while active one 
in color. The residues are numbered according to the Ballesteros-Weinstein numbering scheme [90]. 1100    Current Medicinal Chemistry,  2012 Vol. 19, No. 8  Trzaskowski et al. 
bond network towards the (d/e)Ry motif and GCT peptide (Fig. 
(3B)). The role of this barrier in molecular switching was explained 
by Standfuss et al. [122] based on studies involving the crystal 
structure of rhodopsin with all-trans retinal in the binding site. The 
hydrophobic barrier was described earlier also by Schertler’s group 
[124] upon crystallization of inactive rhodopsin in a trigonal crystal 
form. A more extended motif nPxxy(x)5,6F was proposed by Fritze 
et al. [125] to explain the presence of the interaction between 
Tyr7.53 in TM7 and Phe7.60 in helix H8 in the inactive structure of 
rhodopsin (Fig. (2D). Such an interaction can additionally stabilize 
the inactive state of the receptor. However, in crystal structures of 
other GPCRs, such as the adrenergic and adenosine receptors (Fig. 
(2E-F)) such interaction is not seen despite the fact that Phe7.60 is 
present. It probably indicates that these receptors could be partially 
activated.  
The hydrophobic barrier consists of six residues between 
helices TM2, TM3 and TM6 (Leu2.43, Leu2.46, Leu3.43, Leu3.46, 
Met6.36 and Met6.40) and many of them are conserved in the 
rhodopsin-class of GPCRs. The rearrangement of hydrogen bonds 
is relatively minor but they directly link changes in the CwxP motif 
in the retinal binding pocket with the most conserved residues in 
TM1 (Asn1.50) and TM2 (Asp2.50) and nPxxy in TM7. On the 
cytoplasmic side, the rotation of TM6 opens the hydrophobic 
barrier allowing Tyr5.58 and Tyr5.53 to swing into the protein 
interior. They provide additional interactions with water molecules 
extending the hydrogen bond network toward the hydrophobic 
barrier to the (d/e)Ry motif at the cytoplasmic surface of TM3. The 
ionic lock involving residues in this motif, Glu3.49-Arg3.50 and 
Glu6.30, is broken and allows binding of GCT peptide in a 
position that is occupied by TM6 in a ground state. Thus, rotation 
of TM6 and displacement of Trp6.48 results in a hydrogen bond 
network connecting residues from the retinal binding site to those at 
a cytoplasmic surface critical for activation of G protein. 
Also the recently obtained A2AR-T4-lysosyme structure exhibits 
features of agonist induced rearrangements of a cluster of 
hydrophobic residues in TM3-5-6 near the binding site (Ile3.40, 
Leu5.51, Phe6.44 and Trp6.48) similarly to the active structures of 
2AR [15, 108] and rhodopsin [122, 123]). However, although 
Tyr7.53 from the nPxxy motif is relocated towards the receptor 
center the relocation of TM6 is only 3Å which is much smaller than 
in active rhodopsin (6 Å), nanobody 2AR (8 Å) and in the complex 
with trimeric G protein (14 Å). These changes may be blocked by 
the presence of the fused lysozyme structure. However, the changes 
of residues close to the binding site suggest that this conformation 
resembles the Meta-I structure of rhodopsin which does not allow 
binding to G protein. Possibly in some GPCRs the full adaptation to 
G protein binding may be achieved in the presence of a G protein or 
other interaction partners that stabilize the cytoplasmic domain.  
5.5. The Elusive “Global Toggle Switch”  
The number of conserved motifs found in transmembrane 
helices of the Rhodopsin family receptors is significantly higher 
than in the other GPCR families (see Table 1 and Fig. (1)) 
indicating their potential role in receptor stabilization and 
activation. It was proposed that receptors of the Rhodopsin family 
most probably share the common mechanism of activation - the so-
called "global toggle switch" [66]. According to this model the 
TM6 helix performs a vertical see-saw move around the central 
Pro6.50 residue during receptor activation induced by binding of an 
agonist. The upper part of TM6 is closing around the ligand, while 
the lower (near the intracellular surface) is opening to prepare for 
the G-protein binding. It was suggested that during activation by an 
agonist the rearrangement of TM3 and TM5 also takes place, 
though to a minor extent than in the case of the TM6 movement 
[24]. An accompanying kink in TM7 is induced by changes in the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Rearrangement of hydrogen bond network in rhodopsin during its activation. A. The crystal structure of inactive rhodopsin (Protein Data Bank id 
1GZM). B. The crystal structure of constitutively active Glu3.28Gln mutant of rhodopsin with all-trans retinal unbound from Lys7.43 but still present in the 
binding site (Protein Data Bank id 2X72). Both structures include water molecules (shown as red spheres) which participate in hydrogen bond network. In the 
inactive rhodopsin there is a hydrophobic area consisted of five residues located in helices TM2, TM3 and TM6 (in yellow) which form a hydrophobic barrier 
(area in green) separating residues in CwxP (cyan) and nPxxy (blue) motifs from those of (d/e)Ry motif (orange). In the activated rhodopsin a rotation of TM6 
disrupts the water mediated link between TM6 and TM7 and reorganizes the hydrogen bond network. Two tyrosine residues Tyr5.58 and Tyr7.53 reposition 
and fill the uncovered gap between TM3 and TM6 to extend hydrogen bond network toward (d/e)Ry motif and a fragment of G protein GCT (pink). Figure is 
based on [122]. The residues are numbered according to the Ballesteros-Weinstein numbering scheme [90]. Molecular Switches in GPCRs  Current Medicinal Chemistry,  2012 Vol. 19, No. 8      1101 
hydrogen-bond network between TM7 and TM1, TM2 and TM6 
[21]. 
Using the metal ion site engineering techniques and based on 
the obtained distance constraints for 2-adrenergic receptor Elling 
et al. [126] developed the so-called “global toggle switch” 
mechanistic model. In this model Asp3.32 was an anchoring point 
for monoamine binding in TM3 helix. The authors engineered 
metal ion sites, which activated the receptor, between the 
extracellular parts of TMs. Copper and zinc ions alone and in 
complex with aromatic chelators acted as potent agonists in sites 
constructed between position 3.32 (Asp - known to bind ligand 
directly - or its mutation to His) and the Cys or His mutations of 
specific amino acids at TM6 and TM7 close to the binding site. To 
fulfill the distance constraints the residues involved in the 
orthosteric ligand binding pocket had to move closer to each other 
during receptor activation. In this model an inward movement of 
the extracellular segments, especially those of TM6 and, to some 
extent, TM7, was coupled to the well-established outward 
movement of the cytoplasmic segments of these helices. The 
authors suggested that the pivot points for these vertical seesaw 
movements are the highly conserved proline bends of the involved 
helices. Based on the present crystal structures of 2AR the global 
toggle switch must be modified because only a slight inward 
motion of the extracellular part of TM6 was detected. In rhodopsin 
there is even an increase of the retinal binding site and the same is 
in the case of A2AR – the binding site is smaller for antagonists 
regardless if they are smaller (caffeine) or bigger (ZM241385) than 
the agonist (adenosine). TM3, and not extracellular part of TM6 
which is not moving, is responsible for this shrinkage of the binding 
site. There is an unusual bend on TM3 (close to Val3.32) in 
receptor structures with bound antagonists. This residue (located in 
the same position as extremely important Asp3.32 in receptors for 
monoamine ligands) may be now regarded as a part of the 
agonist/antagonist sensor.  
5.6. Role of Conserved Residues 
Rhodopsin-like GPCRs lack a long N-termini except for PARs 
(protease-activated receptors which do not need agonist-binding to 
be activated) with an N-terminal thrombin-cleaved part releasing a 
tethered ligand, LGRs (GPCRs containing LRRs – leucine-rich 
repeats) interacting with glycoproteins and LDLa (a low-density 
lipoprotein receptor class A). In most Rhodopsin-like GPCRs an 
agonist interacts with extracellular loops and the TM region. 
Although sequence diversity in the TM region is quite high even 
within the Rhodopsin family the motifs involved in the activation 
mechanism are well conserved, i.e. (d/e)Ry, CwxP and nPxxy. In 
Table  1 we indicated all conserved residues in the Rhodopsin 
family of receptors and underlined these which are believed to be 
involved in molecular switches. The residues are also visualized on 
the topological scheme of GPCR (7TM receptor) in Fig. (1).  
In TM1 the most conserved residue is Asn1.50, involved in a 
structural water-mediated hydrogen-bonding network between 
TM1, TM2 (Asp2.50), TM6 (Trp6.48) and TM7 (Asn7.45, Ser7.46, 
Asn7.49, Tyr7.53). The Asn 1.50 residue is an arguable element of 
the receptor activation process, namely the TM3, TM5 and TM7 
movements [21]. The conserved proline residue in TM2 [127], 
either in position 2.58 (e.g. in a recently solved CXCR4 structure) 
or 2.59 (rhodopsin and adenosine receptors), which induces a helix 
kink in the first case or a helix bulge in the latter, is crucial for the 
ligand binding, but does not play a significant role in the receptor 
activation. As in most of GPCRs cysteine residues are highly 
conserved in the Rhodopsin family and form disulphide bridges 
stabilizing the receptor structure. The most important cysteine pair 
is Cys3.25 connected with Cys in EC2. Glu3.28, which is present 
only in the Rhodopsin PDB structure, serves as a counterion with 
the protonated Schiff base in 11-cis-retinal and possibly stabilizes 
an inactive state of opsin [128]. Asp3.32 with Trp7.40 and Tyr7.43 
(instead of Lys7.43, more frequent in the Rhodopsin family – see 
Table 1) are a unique fingerprint only for biogenic and trace amine 
receptors (a G2 group) not shared by any other Rhodopsin-like 
GPCR. Asp3.32 with Tyr7.43 were proved to form the TM3 – TM7 
ionic lock stabilizing the unbound, inactive state of the receptor 
[129]. Asp3.32 is believed to serve as a counterion for the amine 
groups of native ligands [130]. A residue in the 3.36 position is not 
well-conserved in Rhodopsin-like GPCRs, however, it was 
confirmed experimentally by site-directed mutagenesis, that this 
residue interacts with Trp6.48 and stabilizes the inactive state not 
only in the 2-adrenergic receptor (Val3.36, van der Waals 
interactions) [18] but also in serotonin receptors (Ser/Cys/Thr3.36, 
hydrogen-bonding) [129], the opsin subclass (Gly3.36) [131] and 
cannabinoid receptors (Phe3.36 aromatic stacking with Trp6.48 – a 
rotamer toggle switch) [132, 133]. Glu/Gln3.37 is a key residue in 
agonist binding to LH and TSH receptors [134]. A well-conserved 
Leu3.40 residue which is close to Pro5.50 before activation and 
becomes distant after, plays a key role in the TM3 – TM5 
movement [24].  
A well-conserved Trp4.50 is a cholesterol binding-site which is 
visible in the structure of human 2-adrenergic receptor [59]. 
Phe5.47 stacks against Phe6.52 and possibly interacts with agonists 
[88] but still little is known about its function. Phe6.44 together 
with Phe6.52, Leu3.40 and Leu5.51 is forming a hydrophobic and 
aromatic cluster around Trp6.48 involved in conformational 
rearrangements of TM5 [24, 129]. Pro6.50, like Pro7.50, produces a 
helix kink around which TM6 performs movements during 
activation. Tyr7.53 in the nPxxy motif interacts with Phe7.60 in 
helix H8 and forms a molecular switch between active and inactive 
conformation. 
5.7. Role of Extracellular Loops in Ligand Binding and 
Switching 
The extracellular loops also have an influence, although 
sometimes transiently, on ligand binding and could participate in 
some types of molecular switches. The recent crystal structures of 
GPCRs revealed that the part of the receptor extending from the 
orthosteric ligand-binding site in the transmembrane domain to the 
cytoplasmic side is highly structurally conserved. In contrast, the 
extracellular surface of GPCRs is substantially diverse and, 
therefore, could be a target of highly selective drugs. However, still 
little is known about the coupling of the extracellular surface to the 
ligand-binding compartment. Bokoch et al. [135] used NMR 
spectroscopy to investigate ligand-specific conformational changes 
around a salt bridge linking extracellular loops EC2 and EC3 
(Asp192-Lys305) in 2AR. It was demonstrated that small-
molecule hydrophilic drugs that bind within the transmembrane 
core and exhibit different efficacies towards G-protein activation 
(agonist – formoterol, neutral antagonist – alprenolol or unliganded 
receptor, and inverse agonist - carazolol) also stabilize distinct 
conformations of the extracellular surface. Such conformational 
coupling supports the possibility of an efficient allosteric action of 
specific drugs targeting this diverse surface with high subtype 
selectivity. Although the specific salt bridge used to monitor these 
conformations may not be present in other GPCRs it is likely that 
ligand-induced changes at the extracellular surface are relevant for 
other family A GPCRs.  
In adrenergic receptors only one residue in the EC2 loop can 
interact with ligands in the binding site: this is Phe201 in 1AR and 
an equivalent residue, Phe193, in 2AR. A disulphide bridge 
located two residues away from that phenylalanine residue keeps 
the proper conformation of EC2 and assures that such interactions 
with the ligand will be preserved. In the recent crystal structures of 
these receptors with agonists the ligands do not appear to interact 
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of the ligand into the receptor binding site we can notice that the 
ligand may interact transiently with Phe193/201. Therefore, it is 
possible that Phe 193/201, together with other residues from the 
extracellular loops, could participate in the action of molecular 
switches. The binding sites of other receptors with diffusible 
ligands are more spacious so the binding of a ligand is more 
straightforward and could be done without a transient binding to the 
EC2 loop. However, even in those receptors the ligands can interact 
with the EC2 loop. An interesting case is a recent crystal structure 
of a chemokine receptor CXCR4 with a peptide ligand CVX15 
consisting of 16 amino acids [33]. Binding of that ligand involves a 
large number of residues from the EC2 loop and also from the N-
terminus. However, because of the lack of structures of CXCR4 
with agonists, there is no direct data on the involvement of 
extracellular surface residues in molecular switching. Even in the 
case of rhodopsin the EC2 loop, which tightly covers the retinal 
binding site, is moving upon retinal isomerization and this 
movement, from the retinal-binding site, is coupled to the rotation 
of TM5 and to the inward motion of the TM6-EC3-TM7 segment 
[136]. 
The hydrophobic ligands, like retinal in the case of rhodopsin, 
are probably entering the receptor binding site directly from the 
membrane. There are two openings of the retinal-binding site in the 
crystal structure of opsin (ligand-free rhodopsin) [89] one between 
the extracellular ends of TM5 and TM6, and another between TM1 
and TM7. It was suggested that the opening between TM5 and TM6 
could be selective for the uptake of 11-cis-retinal. The smaller 
opening between TM1 and TM7 could be a site for the release of 
all-trans-retinal. A putative external binding site for retinal is 
possibly located in the kink region between TM7 and H8 closely to 
palmitoyl chains [137]. The mechanism of retinal movement is 
potentially significant for vision in the regeneration pathway, the 
disorders of which have been associated with different forms of 
blindness. In the recent structure of CXCR4 there is also a gap 
between EC ends of helices TM5 and TM6 which is filled up by 
lipids. The hydrophobic ligands of this receptor could potentially 
enter the receptor binding site through this hole. However, the open 
question remains which residues could be responsible for sensing 
the ligand type and which ones participate in switching 
mechanisms.  
6. ACTIVATION SCHEMES 
The recent period proved to be very fruitful in GPCR research – 
many new structures were crystallized and, what is even more 
important, first time with agonists (1- and 2-adrenergic [104, 108] 
and adenosine [101] receptors and recently also rhodopsin with all-
trans retinal [122, 123]). This greatly facilitated elucidation of the 
activation scheme of these receptors. Now, another breakthrough 
has been made i.e., the long awaited crystal structure of the 
complex of GPCR with the whole G protein is available [96] and 
one can expect that similar structures of other GPCRs will be also 
available. Possibly, a new and exciting mystery to be solved is the 
allosteric influence of dimers on the process of activation. In a very 
interesting review compiled by Deupi and Kobilka [42] about the 
energy landscapes of GPCR activation it is shown how structural 
changes of GPCRs during their activation can be visualized on 
energy landscapes. Because of high structural similarity of all 
crystallized GPCRs, the activation scheme is probably similar for 
all GPCRs so it is suggested that the receptors are passing through 
the same stages during the activations process. This similarity is 
much higher in the cytoplasmic side of the transmembrane bundle. 
This region contains residues involved in receptor activation and 
binding of a G protein. Similar conformational changes underlying 
activation of GPCRs are also deduced from numerous biochemical 
and biophysical experiments. Probably also a sequence of events is 
nearly identical and involves the following steps: first, small 
changes in TM5 and TM7, then a large change in TM6, and then 
neutralization of Asp3.49 in the (d/e)Ry motif (Fig. (2G-I)). Two-
dimensional energy landscapes seem to be more advantageous over 
one-dimensional energy plots but currently too little is known for 
precise construction of such plots. Possibly new crystal structures 
supplemented by long molecular dynamics simulations will help in 
designing so useful but also elegant and eye-catching charts. 2D or 
even 3D energy plots make possible dissection of the reaction 
pathway into discrete non-sequential conformational changes 
providing alternate routes of activation through the energy 
landscape. In this way some events may be skipped for some 
ligands and a full or partial activation state can still be achieved. 
6.1. Two Types of Activation Paths 
The substantial amount of data obtained from rhodopsin and 
also adrenergic receptor activation can serve as a framework to 
reveal activation of other GPCRs. There are some variations, 
though. It is suggested [42] that the 2AR is not trapped in a fully 
inactive conformation in the absence of agonist but its internal 
flexibility allows the receptor to explore different conformations. 
This may suggest a shallow energy landscape with several 
conformational states separated by relatively low energy barriers. 
On the contrary, for rhodopsin (and similarly activated GPCRs) it is 
supposed that binding of agonist is invoking an induced fit of the 
receptor structure. Therefore, agonists have to bind to the receptor 
with high affinity and this high binding energy is used to initiate 
conformational changes (“jump”) over the highest initial barrier of 
energy. Retinal isomerization in rhodopsin provides such high 
energy. In case of other receptors (although being classified in the 
Rhodopsin-like family because of their sequence) the ligands have 
relatively low affinity and rapid dissociation rates; these features 
may indicate a conformational selection procedure of activation. 
After ligand binding the sequence of events during receptor 
activation is regarded as being similar in all these receptors. Any 
differences are rather not in a number of steps required for full 
activation but rather in the size of energy minima depths. The well-
known example of differences in the activation scheme is the 
existence of an open ionic lock in crystal structures of 1AR and 
2AR adrenergic receptors with antagonists and inverse agonists 
bound that may suggest a very low energy barrier for opening of 
this switch. The late stages of 2AR activation, which are supposed 
to be analogous to achieving the Meta-II stage in rhodopsin 
activation, involve a similar set of conformational changes, i.e. 
rearrangement of TM6 and neutralization of Asp3.49 in the (d/e)Ry 
motif of TM3. According to the above two schemes of activation, 
the partial agonism can be also explained in two ways. For those 
GPCRs from which partial agonists dissociate faster than full 
agonists, not all binding events last long enough to promote 
activation of the G protein. Another possibility is that the partial 
agonists stabilize different intermediate conformations that lead to 
alternate activation pathways and to non-optimal G protein 
activation. Particular steps can be achieved either by induced fit 
upon binding of a ligand or by conformational selection but the 
achieved equilibrium states would be completely indistinguishable. 
It is suggested that the induced fit mechanism is present in 
rhodopsin and angiotensin AT1 receptor whereas 2AR may 
function by selecting specific receptor substates by the ligand. 
7. THEORETICAL STUDIES ON THE ACTION OF 
MOLECULAR SWITCHES 
7.1. Single TM Studies 
One of the first computational studies aimed at GPCRs switches 
was done in 2001 by Ballesteros et al. [113] who simulated the 
disruption of the TM3-TM6 ionic lock. Simulations presented in 
that work concerned only TM6 and short MD runs to simulate the 
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those computational studies combined with experimental mutations 
of the Glu6.30 residue it was concluded that a conformational 
rearrangement of TM6 is highly correlated with the extent of 
constitutive activity of different mutants. A similar approach was 
used later to study the conformational switch in the 5-HT2C receptor 
[138]. Again, a combined computational-experimental study 
showed that a conserved Tyr7.53 residue is interacting with the 
conserved Tyr7.60 (in helix 8) contributing to the switching of the 
receptor among multiple active and inactive conformations. 
Although the ‘ionic lock’ is still regarded as an important switch it 
can be open in crystal structures of GPCRs even with antagonists 
and inverse agonists. Currently, only in the inactive and partially 
active rhodopsin structure (batho and lumi intermediates) that 
switch is closed [139].  
A similar approach was presented in the 2002 paper by Shi et 
al. [140]. In this work Monte Carlo techniques were used to sample 
rotamer changes among the X6.47- Trp6.48-Phe6.52 residues of the 
human 2AR model of TM6. The results show a high correlation 
between the conformation of side chains of these residues and the 
helix kink at the Pro6.50 position, which was consistent with the 
experimental data for rhodopsin [141]. While it was clear that 
simulations on isolated helices could not predict the global 
interaction and changes in GPCRs, the results showed the 
usefulness of computational methods for studying ionic locks. 
The same ionic lock has been studied in the 5-HT2A system in 
the 2002 paper by Visiers et al. [142]. Here, authors decided to 
concentrate on the electrostatic properties of the conserved residues. 
By solving the Poisson-Boltzman equation to obtain electrostatic 
potentials of the different conformers of important residues on the 
TM3-TM6 model, it was found that Glu3.49 may undergo 
protonation upon activation of the GPCR. The activation of the 
protein has been also explained as a change in the kink at Pro6.50 
which allows the ends of TM3 and TM6 to move away from each 
other. Based on the computational results it was suggested that 
selected, single-point mutations (Glu6.30Asn, Glu6.30Gln, 
Glu6.30Leu) would disrupt the electrostatic interactions of the 
(d/e)Ry motif with this residue. This prediction was confirmed later 
by the results of site directed mutagenesis, where it was shown that 
a neutral residue at the 6.30 position increases the activity of 5-
HT2A in the absence of the ligand, similarly to the human 2AR 
case. 
7.2. Studies on a Complete GPCR Model 
7.2.1. Investigations of the Ionic Lock Switch 
The most prominent method to study the dynamics of GPCRs is 
nowadays Molecular Dynamics (MD) of the complete GPCR 
model. One of the first MD simulations focusing on TM3-TM6 
ionic locks was performed in 2002 by Greasley et al. [143], who 
simulated the 1AR model based on the rhodopsin structure of 
Palczewski. The methodology used the united atom model and 
included a large number of short (150 ps) MD runs of the protein 
only (without environment), using NOE constraints to preserve the 
-helix structure of TMs. The short time of simulations was due to 
the limited computational resources available at that time. The 
results showed a very high stability of the Arg3.50-Glu6.30 salt 
bridge. Combined with experimental mutational data (Glu6.30 
mutations that weakened this ionic lock constitutively activated the 
receptor) the results showed that the transition from the inactive to 
active state of 1bAR involves a rearrangement of helices TM3 and 
TM6. The structure of 1bAR is still not available but predicted 
movements were confirmed by crystal structures of activated 1- 
and 2-adrenergic receptors. 
In the same year Rohrig et al. presented their work in which a 
full-atom model of the bovine rhodopsin has been immersed in a 
layer of a n-octane mimicking lipid bilayer [144]. The goal of these 
simulations was to show the effect of retinal cis-to-trans 
isomerization on the dynamics of the protein. Indeed, it was found 
that retinal isomerization serves as a trigger for propagation of the 
signal to the surrounding helices. Despite the limited simulation 
time authors were able to see some rearrangements in TM6 and to a 
lesser extent also in TM4 and TM5. They have also noticed 
cleavage of selected hydrogen bonds in these helices, however the 
ionic lock remained stable over the course of simulations. In 2003 a 
team led by Thomas B. Woolf applied MD simulations to the full 
atom bovine rhodopsin model including DOPC lipid membrane and 
surrounding by water molecules [145]. Their 40 ns simulation (a 
huge amount in those days) became a basis for a number of similar 
MD simulations on GPCRs in the following years. Similarly to the 
Rohrig studies this work concentrated on the rhodopsin vicinity and 
the changes in residues interacting directly with the rhodopsin 
ligand. The authors noted a strong interaction between residues 
forming the ionic lock (Arg3.50-Glu6.30) throughout the whole 
simulation time (as in Fig. 2G). 
A similar approach as in the Crozier work has been applied to a 
large number of GPCR MD studies, although the advances in 
computational powers allowed to lengthen the simulation scale to 
tens and hundreds of nanoseconds. One of the interesting works 
showing the stability of various locks was the MD investigation of 
the opioid receptors models. In the μ-OPR opioid receptor there is 
no glutamic acid residue in the 6.30 position, but the TM3-TM6 
lock is still present in the modeling studies due to the hydrogen 
bond between Arg3.50 and Thr6.34 [117, 118]. In the most recent 
simulations this lock remains unbroken even in the presence of 
selected antagonists or agonists [119, 120], most possibly because 
of a rather short length of simulations (nanosecond time scale) 
compared to the time needed for activation of the receptor 
(milliseconds). Binding of antagonists has also no effect on the 
Trp6.48 rotamer switch which remains in the initial, rhodopsin-like 
vertical position. Interestingly, μ-OPR agonists toggle the Trp6.48 
position to a horizontal one which, during simulations, forces the 
change in positions of aromatic residues around the highly 
conserved Pro6.50. It is also worth noticing that the mutation of 
Leu6.30Glu in the μ-OPR system inactivates this receptor [146]. 
Simple calculations of the electrostatic interactions for two helices 
(TM3 and TM6) have shown that the Leu6.30Glu mutation 
enhances the hydrogen bond network around the mutated residue 
and stabilizes the inactive state. 
7.2.2. Breaking of the 3-7 Lock Switch 
During the MD simulations of μ-OPR it was noticed that 
another switch, the 3-7 lock, a link between TM3 and TM7 (a 
hydrogen bond Asp3.32-Tyr7.43), remains stable for the apo-
protein simulations and in the presence of antagonists. The presence 
of agonists, however, forced the hydrogen bond to break [118]. For 
one of the agonists it was also shown that rotation of Trp6.48 was 
linked to the cleavage of the Asp3.32-Tyr7.43 hydrogen bond and 
occurred within 1 ns after its breaking. Later, MD studies have 
shown that a similar cascade of events is likely to occur also upon 
agonist binding and activation of -OPR and -OPR [119]. 
Recently, a structurally similar -OPR agonist and antagonist pair, 
guanidinonaltrindole (GNTI) compounds, were investigated by 
molecular dynamics simulations [120]. 5-GNTI is an antagonist 
while 6-GNTI is an agonist. Ligands were relaxed in the receptor 
binding site by the simulated annealing routine. During a series of 
MD simulations of the ligand-receptor complexes in DPPC 
membrane, the 3-7 lock was broken when the agonist was bound, 
but remained unbroken upon binding of the antagonist. The 
hypothesis of 3-7 lock breaking on the agonist binding still awaits 
confirmation, since no experimental structure of any opioid receptor 
is available at this time. 
7.2.3. Beyond Classical MD Techniques 
In 2009 Provasi et al. studied the dynamics of the -OPR 
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for an efficient exploration of multidimensional free energy 
surfaces of GPCRs (and other biological systems) by adding a 
history-dependent bias to the interaction potential of the system. 
The required microsecond-scale well-tempered metadynamics has 
been achieved using the united-atom model for lipids (DPPC and 
cholesterol molecules) and the full-atom model for protein and 
ligand. It allowed the authors to suggest a preferential entry 
pathway of the NLX antagonist, starting from the -OPR surface 
and ending in the proper binding pocket of the GPCR, and to 
evaluate the bonding constants for the ligand. The observed binding 
pocket was extremely close to the previously predicted one and the 
starting structure for their system had all the known locks including 
the Arg3.50-Thr6.34 of TM3-TM6 lock (or ‘3-6 lock’ instead of 
‘ionic lock’ since no salt bridge can be formed in this case) and the 
Asp3.32-Tyr7.43 of 3-7 lock.  
It is also worth mentioning that other computational techniques 
have been used to model the activation of rhodopsin and they gave 
similar results. In 2006 Niv et al. used an Elastic Network Model to 
study the inactive form of rhodopsin [148]. In this model a 
harmonic potential with a single force constant accounts for 
pairwise interactions between all C atoms within a certain cutoff 
distance. The analysis of the structural relation of the inactive 
normal modes to the transition vectors towards the active 
conformations has been discussed. It has been found that the active 
form of rhodopsin should be characterized by structural changes in 
TM5-6-7, while helices TM1-2-3-4 were shown to be the most 
stable ones which were confirmed later by crystal structures of 
Meta-II rhodopsin. Niv et al. also predicted the rotamer toggle 
switching of Trp6.48 and they claimed that it was in agreement 
with the early spectroscopic data [149]. However, this was not 
confirmed by later crystal structures of opsin and also rhodopsin 
with all-trans-retinal bound [123] and unbound but still present in 
the binding site [122]. The spectroscopic properties of Trp6.48 
really change during activation of rhodopsin but it is a result of 
large movement of cytoplasmic part of TM6 and smaller 
movements of adjacent helices so a local environment of Trp6.48 is 
altered even if a rotamer of Trp6.48 itself does not change.  
Much more detailed approach to the study of ionic-lock induced 
activation of GPCRs has been proposed in the work of Balamaran 
et al. [150]. In this work the all-atom force field has been used to 
evaluate the relative stability of various point-mutations in 1-
adrenergic receptor. The results showed good correlation with the 
experimental data for over 90 single and multiple point mutants of 
this protein. It was found that Tyr5.58Ala and Val5.61Ala 
mutations stabilize the Arg3.50–Glu6.30 ionic lock, while 
Phe7.48Met mutation alters the interaction between the conserved 
NPxxY motif of TM7 and TM8.  
7.2.4. Consequences of the Ionic Lock Instability and TM 
Movements 
The first experimental structure of GPCR, opsin, provided 
structural data which confirmed the importance of molecular 
switches and ionic locks [89]. While some of the structures of the 
early photoproducts of rhodopsin showed only an increased 
Arg3.50-Glu6.30 distance [139], in the opsin structure these 
residues are no longer interacting with each other. Arg3.50 is 
released from the Glu6.30 and Glu3.49 interactions and engages 
with Tyr5.58 on TM5, an interaction that was not suggested before. 
At the same time a new interaction between Lys231 and Glu247 is 
formed to stabilize TM5-TM6 interactions. Also, the Tyr7.53 of the 
nPxxy motif (TM7) aromatic stacking interaction with Phe7.60 
(H8) is broken due to a different orientation of the helices. On the 
other hand the Trp6.48 toggle switch is in exactly the same position 
as in the inactive rhodopsin, even though it was indicated by NMR 
studies that it must change its position and interaction partners 
during activation [151].  
A very similar structure of the active opsin, albeit with a 
different Trp6.48 rotamer, has been predicted computationally by 
Bhattachary et al. at the same time [152]. The authors started from 
the inactive (dark) state and have predicted TM conformational 
changes that are induced by the isomerization of 11-cis retinal to 
all-trans retinal with good accuracy. In another study Hornak et al. 
used nanosecond MD guided by NMR distance restraints to 
simulate the activation of rhodopsin [153]. Results of this work 
were also in agreement with experimental data and showed the 
coupling of retinal isomerization to the motions of helices and 
activation of the receptor which proceeds via a series of multiple 
switches. 
To solve this inconsistency in behavior of Trp6.48, a MD 
simulation of 2AR and bovine rhodopsin systems combined with 
mutational analysis of the ghrelin receptor was performed [154]. 
The 8 ns simulation of inactive rhodopsin with 11-cis-retinal 
present, showed no change in the Trp6.48 conformation. The 
removal of retinal, however, allowed this residue to change its 
rotameric state. After additional 9 ns of simulation Trp6.48 
established a moderately strong and not very stable interaction with 
Phe5.47 on TM5. In the 2AR case removal of its ligand (carazolol) 
did not result in large conformational changes of Trp6.48 and no 
additional interactions have been observed. Additional data 
obtained from metal ion site engineering confirm the close 
proximity of these two residue. Mutational data from ghrelin 
receptors experiments show, on the other hand, that both of these 
residues are important for constitutive activity and agonist-induced 
efficacy. Authors suggest that the ionic lock may be one of the 
several molecular switches that form an allosteric interface between 
the TMs performing global toggle switch movements that mediate 
the intramolecular signal which leads to G protein activation. 
However, since ~30% of GPCRs lack the Trp6.48 residue, it may 
not be a part of the general activation pathways for 7TM receptors. 
The problem of the lack of interaction between Arg3.50 and 
Glu6.30 in the 2AR crystal structure, despite their presence in the 
sequence, has been addressed in a 2009 paper by Dror et al. [155]. 
For this system there was also a variety of biochemical evidence 
suggesting that an ionic lock between those residues is formed in 
the inactive state [143]. It was suggested that the broken lock may 
be a consequence of the techniques used to stabilize 2AR for 
crystallization or of the binding of carazolol or timolol, which 
might reflect the ability of some partial agonists to induce signaling 
through disruption of this interaction. An all-atom simulation of 
2AR over 10 microseconds showed that an ionic lock forms 
reproducibly both in apo 2AR and in the carazolol-bound system. 
Interestingly, the ionic lock had a tendency to break in simulation 
every few hundred nanoseconds and the conformation with this 
lock broken remained stable for tens of nanoseconds. In conclusion 
the authors suggested that the inactive 2AR alternates between 
several major conformations with the ionic lock present and a few 
minor conformations without the ionic lock. Their long, 
microsecond simulation time allowed to describe the inactive state 
of this GPCR as an ensemble of states. 
Almost at the same time another MD work on 2AR and 1AR 
appeared [156]. 500 ns MD runs for carazolol-bound 2AR model 
and cyanopindol-bound 1AR model showed the formation of the 
ionic lock, which remained stable during the stimulation runs, in 
both systems. In this work no breaking of the ionic lock has been 
observed; however, the timescale of the simulations might have 
been too short for such event to occur. Interestingly, water-
mediated interactions Trp6.48-Asp2.50 and Asp2.50-Asn7.49-
Tyr7.53 have been observed, some of which have been suggested to 
be important in activation of the thyrotropin receptor. The water-
mediated hydrogen bonds also remained stable during the 
simulation runs. The results of this study were different than the 
earlier theoretical investigation of the impact of ligand binding on 
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investigated the perturbations in the helical rotational orientations 
induced by ligand binding in the TM region of the 2-adrenergic 
receptor [157]. They found that norepinephrine (full agonist) and 
dopamine (a weak partial agonist) break the Arg3.50–Glu6.30 ionic 
lock and engage the Trp6.48 rotamer toggle switch, while 
salbutamol (a partial agonist) only breaks the ionic lock and 
catechol (a very weak agonist) only switches the rotamer toggle.  
A longer, 1.02 microsecond simulation of 2AR presented by 
Romo et al. allowed the researchers to show the interconversion 
between ionic lock substates [158]. Similarly to previous results 
authors showed that the Arg3.50-Glu6.30 ionic lock is able to break 
and reform in the wild-type 2AR simulations. The lock-breaking 
event is followed by the reorganization of the cytoplasmic end of 
TM6 through a clockwise rotation of the helix and movement of the 
end of TM5 away from TM6. These events were in agreement with 
the predicted activation models of this system. In 2011 
Moukhametzianov et al. followed the work of Dror and showed that 
also  1AR may have at least two distinct conformations in the 
inactive state [159]. Their new X-ray structures of this receptor 
show that TM6 and IC3 loop (connecting TM5 and TM6) may have 
a bent form, stabilized by previously unseen interactions Met281-
Leu282 and His286-Gln237. They also noticed that the new TM6 
conformation positions Arg3.50 and Glu6.30 only 3.8 Å apart, 
which is a distance significantly longer than in the rhodopsin case 
(with the ionic lock), but also much shorter than in the other 
conformation of TM6 (where the distance is 6.2 Å). 
Experimental structures of active states of rhodopsin and 2AR 
have shown that MD predictions of the behavior of ionic locks 
during activation were generally accurate. The constant 
development of computational methods and the more and more 
powerful computers allow us now to reach microsecond simulations 
[107, 160-162] and obtain information about the general energy 
landscapes of GPCRs. Such theoretical energy landscapes and 
activation pathways, even though simplified to include only one or 
a few coordinates, give a very good means to look inside the GPCR 
activation mechanisms. The latest experimental results, e.g. 
highlighting the role of the highly-conserved Tyr5.58 in the 
stabilization of the active state of rhodopsin [163] are perfect 
examples of data and events that may be simulated by 
computational methods to gain more understanding of their 
mechanism of activation/inactivation and molecular processes 
involved in them. 
8. DRUG DESIGN 
Development of selective drugs for GPCRs is challenging 
because (1) there is a high degree of homology among many closely 
related receptor subtypes that can regulate diverse physiological 
functions; (2) a single receptor may couple to more than one G 
protein or even signal through G protein independent pathways; (3) 
a receptor can be regulated by multiple allosteric ligands (small 
molecules but also proteins including GPCRs – what implicate 
allosteric influence by dimerization or oligomerization either 
homomers or heteromers; (4) predominant signaling behavior of 
GPCRs may differ in different cells or organs.  
Despite the progress which led to insights into the three-
dimensional structures of GPCRs in both active and inactive states, 
the process of developing a drug for a particular GPCR target has 
become more complex, time-consuming and expensive [164]. 
Detailed characterization of agonist and antagonist binding 
behavior provided insight into the allosteric effect of G proteins on 
receptor structure and agonist binding affinity. The efficacy of 
ligands for activating the arrestin pathways can differ from those 
that activate G proteins. Some ligands possess a complex 
pharmacological behavior acting as agonists and simultaneously 
antagonists or inverse agonists depending on the pathways they 
activate and inactivate. Carvedilol is an inverse agonist for 2AR 
activation of Gs but a partial agonist for 2AR activation of arrestin 
[165]. The complexity of GPCR signaling pathways and ligand 
efficacy profiles complicate the process of drug discovery. 
Moreover, specific receptors might exhibit cell type-specific 
signaling as a consequence of the cell-specific complement of 
different proteins: signaling, regulatory and scaffolding. 
As can be seen from crystal structures the structural diversity of 
GPCRs is much greater for amino acids lining the pathway into the 
ligand binding pocket. Although these amino acids do not make 
direct contact with a bound ligand the size of carazolol, they could 
contribute to initial transient interactions between the ligand and 
receptor that affect the ligand association rate. These residues might 
also play a role in binding larger ligands that extend into the 
vestibule of the binding pocket, such as the long-acting 2AR 
agonist, salmeterol, that is used in the treatment of asthma [164]. 
The recent crystal structure of the chemokine CXCR4 receptor with 
an antagonist in the form of a peptide ligand, which extends from 
the receptor binding side toward the extracellular surface, show 
such kind of binding for the first time for GPCRs (PDB id 3OE0) 
[33]. Although many aspects of GPCR function can be explained by 
a simple two-state model, evidence from biophysical and functional 
studies support a multistate model in which ligands stabilize a 
specific conformational state or set of states [42] making the 
complexity of GPCR signaling similar to the microprocessor work 
[166].  
9. CONCLUSIONS 
Investigations of molecular switches in the superfamily of 
GPCRs is extremely challenging but may be truly rewarding 
because the detailed mechanism (or mechanisms) of activation of 
these receptors could help to design highly selective drugs acting 
not even on a single receptor subtype but on a single 
pharmacological receptor subprofile. Because of the intrinsic 
instability of GPCRs resulting in their multiple functionality, the 
investigations must proceed via elucidation of multiple structures 
with inverse agonists, antagonists and agonists, possibly also with 
trimeric G proteins and arrestins. Dimerization is a separate large 
issue currently unresolved but possibly the allosteric action of 
GPCRs  via  dimerization is the most common mechanism 
influencing receptor functioning. GPCRs are the biggest and one of 
the most mysterious single group of molecular targets for drugs, 
therefore, one can be sure that studies on their structures and 
mechanisms will be continued with an increasing pace.  
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5-HT =  5-hydroxytryptamine 
AFM =  atomic  force  microscopy 
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DPPC =  dipalmitoylphospatidylcholine 
EC =  extracellular 
F-D =  force-distance  curves 
FRET  =  fluorescence resonance energy transfer 
GABA = gamma-aminobutyric  acid 
GDP =  guanosine  diphosphate 
GNTI =  guanidinonaltriondole 
GPCR = G  protein-coupled  receptor 
GRK =  GPCR  kinase 
GTP =  guanosine  triphosphate 
HBD =  hormone-binding  domain 
HTS =  high-throughput  screening 
IC =  intracellular 
LRR =  leucine-rich  repeat 
Mab5 =  monoclonal  antibody  5 
MD =  molecular  dynamics 
mGlu =  metaboprotic  glutamate 
MPEP = 2-methyl-6-(phenylethynyl)-pirydine 
NAM =  negative  allosteric  modulator 
OPR =  opioid  receptor 
PAM =  positive  allosteric  modulator 
SMD  =  steered molecular dynamics 
SMFS  =  Single Molecule Force Spectroscopy 
T4L =  T4  lysozyme 
TM =  transmembrane  region 
VFTM = Venus  flytrap  module. 
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